NasdaqGS:AGIOBiotechs
Agios Pharmaceuticals (AGIO): Reassessing Valuation After FDA Delays Thalassemia Decision for PYRUKYND Expansion
Agios Pharmaceuticals (AGIO) is back in focus after the FDA missed its December 7 decision date on the mitapivat thalassemia sNDA, leaving the filing under active review and investors recalibrating timing expectations.
See our latest analysis for Agios Pharmaceuticals.
The missed PDUFA date seems to have cooled near term enthusiasm, with a roughly 35 percent 1 month share price return decline and a 1 year total shareholder return of about negative 38 percent. This signals fading momentum...